Meeder Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Meeder Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3K	Sell	55 -67	-55%	-$3.53K	﹤0.01%	898
2026 Q1	$5.8K	Buy	122 +81	+198%	+$4.27K	﹤0.01%	801
2025 Q4	$2.15K	Sell	41 -5	-11%	-$299	﹤0.01%	865
2025 Q3	$2.98K	Buy	+46	New	+$2.64K	﹤0.01%	746
2021 Q2	–	Sell	-46	Closed	-$6K	–	2530
2021 Q1	$6K	Buy	+46	New	+$6.95K	﹤0.01%	1781
2020 Q2	–	Sell	-12	Closed	-$1K	–	2125
2020 Q1	$1K	Hold	12	–	–	﹤0.01%	2172
2019 Q4	$1K	Buy	+12	New	+$655	﹤0.01%	2124

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Meeder Asset Management's CRSP Position: Q2 2026 in Review

Meeder Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 55% in Q2 2026, selling an estimated $3.53K and leaving 55 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #898.

Meeder Asset Management first reported a position in CRSP in Q4 2019 and has held it in 7 quarters since. The position peaked at $6K in Q1 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Meeder Asset Management held 55 shares of CRISPR Therapeutics worth $3K as of Q2 2026.
Meeder Asset Management sold 67 CRISPR Therapeutics shares in Q2 2026, an estimated $3.53K.
CRISPR Therapeutics made up ﹤0.01% of Meeder Asset Management's portfolio in Q2 2026, its #898 holding.
Meeder Asset Management first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 7 quarters since.
Meeder Asset Management's CRISPR Therapeutics position peaked at $6K in Q1 2021.
524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.